Studies leading up to the FDA approval found that people with hand eczema who used the cream were more likely to improve than ...

The FDA approved Anzupgo for the treatment of moderate to severe chronic hand eczema in adults who do not adequately respond ...

The FDA has approved delgocitinib cream as a topical treatment for moderate-to-severe chronic hand eczema (CHE) in adults, ...

Adult patients with moderate to severe hand eczema with previous treatment failure or in whom topical corticosteroids are ...

LEO Pharma Inc. announced today that the Food and Drug Administration (FDA) has approved ANZUPGO® (delgocitinib) cream for ...

Danish dermatology specialist Leo Pharma has scored an FDA approval that makes its JAK inhibitor cream Anzupgo (del | Despite chronic hand eczema affecting 1 in 10 people worldwide, there was no ...

The topical JAK inhibitor is the first treatment approved specifically for adults with moderate-to-severe chronic hand eczema.

Ballerup, Denmark Saturday, July 26, 2025, 15:00 Hrs [IST] ...

The first therapy specifically indicated for chronic hand eczema (CHE) has passed muster at the FDA.

LEO Pharma’s Anzupgo (delgocitinib) cream has been approved by the US Food and Drug Administration (FDA) to treat adults with ...

Becoming the first approved treatment for chronic hand eczema in the U.S., Leo Pharma A/S’s Anzupgo (delgocitinib) received ...